Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 20, 2010 at 10:00 am Eastern; Webcast Will Be Available
ROCKVILLE, Md., May 19, 2010 (BUSINESS WIRE) –Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will hold its Annual Meeting of Stockholders on Thursday, May 20, 2010 beginning at 10:00 am Eastern Time at the Willard InterContinental Washington, 1401 Pennsylvania Avenue NW, Washington, DC 20004.
At the annual meeting, stockholders will consider and vote on the following matters:
- the election of Fuad El-Hibri, Jerome M. Hauer and Ronald B. Richard to serve as Class I directors, each for a term of three years; and
- the ratification of the selection by the audit committee of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2010.
Stockholders also will consider and vote on any other matters as may properly come before the annual meeting or any adjournment or postponement thereof. The company’s board of directors has no knowledge of any other matters which may come before the meeting.
Stockholders of record at the close of business on March 24, 2010 are entitled to notice of, and to vote at, the annual meeting or any adjournment or postponement thereof.
Following the formal portion of the meeting, a member of the company’s senior management will provide a brief corporate update, including a discussion of the company’s business activities, financial outlook and current news.
Interested parties may listen to the Annual Meeting via webcast by visiting the Emergent BioSolutions website at www.emergentbiosolutions.com. The webcast will be archived on the company’s website under “Investors”.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Investor Contact Robert G. Burrows Vice President, Investor Relations 301-795-1877 BurrowsR@ebsi.com or Media Contact: Tracey Schmitt Vice President, Corporate Communications 301-795-1800 SchmittT@ebsi.com